Protara Therapeutics, Inc.
TARA
NASDAQ·Healthcare·Biotechnology·Mkt cap $223.1M
$3.97
▲ +0.76%
P/E
-3.18
Mkt Cap
$223.1M
52-Wk Range
$3.02–$7.82
52-Week Range
$3.02 - $7.82
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 25.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Orphan drug designation and potential for expedited regulatory pathways
- First-mover advantage in cell therapy for lymphatic malformations
- Focused pipeline targeting underserved rare disease populations with limited alternatives
- Clinical-stage validation reducing early-stage development risk
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of TARA-002 through clinical development stages toward potential FDA approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-10.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TARA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 11, 2026
Reported EPS of -$0.36 vs -$0.33 consensus (-10.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-10.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$180.0K
Margins · last 8Q
Gross
50.0%
Profit
-12037.8%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · May 20, 2026
vs Industry
How TARA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related